Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$144.13
-55.35% vs spot
Sell
Spot price
$322.81
Mkt cap $22.81B
subtle cardAnalyst PT consensus
$315.83
-2.16% vs spot
subtle cardMethods covered
18 / 19
15 in blend
subtle cardFootball field
WST · fair-value range by method
Method comparison
WST · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $184.74 | $142.41 – $246.53 | -42.77% | 22.3% | WACC 8.6%, g₀=13.8%, gₗ=2.0% | high |
| DCF · FCFE | dcf | $151.43 | $118.21 – $197.98 | -53.09% | 16.8% | kₑ 9.7%, g₀=13.8%, gₗ=2.0% | high |
| DDM · Gordon | ddm | $12.35 | $10.93 – $14.20 | -96.17% | — | D₁ 0.93, kₑ 9.7%, gₗ 2.0% | med |
| DDM · H-model | ddm | $19.47 | $15.62 – $24.48 | -93.97% | — | D₀ 0.93, g₀=13.8%, gₗ=2.0%, H 5y | med |
| DDM · multi-stage | ddm | $16.00 | $13.60 – $18.40 | -95.04% | 5.6% | 5y schedule 13.8% → 2.0%, kₑ 9.7% | high |
| Residual income | income | $54.91 | $48.32 – $61.50 | -82.99% | 11.2% | BV 48.26, ROE 15.5% → kₑ | high |
| EVA / MVA | income | $160.02 | $140.82 – $179.23 | -50.43% | 7.8% | IC 2.8B, WACC 8.6% | high |
| P/E · sector | multiple | $149.60 | $131.65 – $167.55 | -53.66% | 13.4% | EPS 6.80 × peer P/E 22.0 | med |
| P/S · sector | multiple | $186.84 | $158.81 – $214.86 | -42.12% | 3.4% | Rev/sh 46.71 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $170.64 | $150.16 – $191.11 | -47.14% | 11.2% | EBITDA × peer 15.0× − ND -0.4B | high |
| EV / EBIT | multiple | $174.57 | $148.39 – $200.76 | -45.92% | 2.2% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $164.51 | $139.83 – $189.18 | -49.04% | 2.2% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $182.23 | $154.89 – $209.56 | -43.55% | 1.1% | PEG=1, fwd EPS g 26.8% | med |
| Earnings power | intrinsic | $92.34 | $81.26 – $103.42 | -71.40% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $241.53 | $205.30 – $277.75 | -25.18% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $93.51 | $79.48 – $107.54 | -71.03% | 0.6% | PE = g (13.8) | low |
| Book NAV | asset | $48.26 | $45.85 – $50.68 | -85.05% | 1.1% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $32.40 | $27.54 – $37.27 | -89.96% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g 30.4% · Heroic — market needs ≥25% FCF growth | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (1.17)β | × 1.17 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 9.68% |
| Pre-tax cost of debtkd | 0.14% |
| Effective tax ratet | 20.9% |
| After-tax cost of debt | 0.11% |
| Equity weight$3.2B | 88.4% |
| Debt weight$0.4B | 11.6% |
| WACC | 8.57% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 8.33% |
| Analyst forward EPS growthFMP | 26.80% |
| Historical 5y revenue CAGRFY | 2.08% |
| Historical 5y EPS CAGRFY | -5.89% |
| Sustainable g (ROE × retention)Δ | 13.62% |
| Blended near-term growth (g₀) | 13.75% |
| Terminal growth (gₗ) | 2.00% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2023-12-31)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $315.83
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.